An Open-label, Multicentre, Dose Escalation Phase Ib Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Therapeutic Activity of RO7009789 (CD40 Agonist) in Combination With MPDL3280A (ANTI−PD-L1) in Patients With Locally Advanced and/or Metastatic Solid Tumours.
This is an open-label, multicentre study designed to assess the safety, pharmacokinetics,
pharmacodynamics and activity of RO7009789 administered in combination with MPDL3280A in
patients with metastatic or locally advanced solid tumours. The study will be conducted in
three parts (I, II, and III), with part I divided into parts IA and IB and into subcutaneous
(s.c.) and intravenous (i.v.) treatment groups. All patients will be followed up for
survival until death or loss of follow-up after the last visit or withdrawal of consent.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society